WHAT IS CLAIMED IS:

1. A compound represented by formula (1):



(1)

wherein A is an optionally substituted a phenyl or heterocyclic group which has 1 to 4 substituents selected from the group consisting of a halogen atom, a hydroxyl group, an amino group, a nitro group, a cyano group, an alkyl group having 1 to 4 carbons, an alkoxy group having 1 to 4 carbons, an aminoalkyl group having 1 to 4 carbons, an alkylamino group having 1 to 4 carbons, an acyl group having 1 to 4 carbons, an acylamino group having 1 to 4 carbons, an alkylthio group having 1 to 4 carbons, a perfluoroalkyl group having 1 to 4 carbons, a perfluoroalkyloxy group having 1 to 4 carbons, a carboxyl group, an alkoxycarbonyl group having 1 to 4 carbons, a phenyl group and a heterocyclic group;

X is a bond or a moiety having a structure selected from those illustrated in formula (2):



(2)

wherein e is an integer of 1 to 4; g and m are independently an integer of 0 to 4; R^4 is a hydrogen atom or an optionally substituted alkyl group having 1 to 4 carbons, or the acyl group represented by formula (3)



(3)

wherein R^6 is an optionally substituted alkyl group having 1 to 4 carbons, a perfluoroalkyl group having 1 to 4 carbons, a phenyl group or a heterocyclic group; R^5 is a hydrogen atom or an optionally substituted alkyl group having 1 to 4 carbons;

n is an integer of 0 to 4, provided that when X is a bond, n is not zero;

Q is a moiety having a structure selected from those illustrated in formula (4)



(4)

wherein R^7 and R^8 are independently a hydrogen atom or an optionally substituted alkyl group having 1 to 4 carbons;

R^1 and R^2 are independently a hydrogen atom, a halogen atom, a hydroxyl group, an amino group, an alkyl group having 1 to 4 carbons, an alkoxy group having 1 to 4 carbons, an aminoalkyl group having 1 to 4 carbons, an alkylamino group having 1 to 4 carbons, an acyl group having 1 to 4 carbons, an acylamino group having 1 to

4 carbons, an alkylthio group having 1 to 4 carbons, a perfluoroalkyl group having 1 to 4 carbons, a perfluoroalkyloxy group having 1 to 4 carbons, a carboxyl group or an alkoxycarbonyl group having 1 to 4 carbons;

R^3 is a hydroxyl or amino group

or a pharmaceutically acceptable salt thereof.

2. A benzamide derivative or a pharmaceutically acceptable salt thereof as claimed in Claim 1, wherein n is an integer of 1 to 4.

3. A benzamide derivative or a pharmaceutically acceptable salt thereof as claimed in Claim 2, wherein Q is selected from the structures illustrated in formula (5):



(5)

wherein R^7 and R^8 are as defined above.

4. A benzamide derivative or a pharmaceutically acceptable salt thereof as claimed in Claim 3, wherein A is an optionally substituted hetero ring.

5. A benzamide derivative or a pharmaceutically acceptable salt thereof as claimed in Claim 4, wherein A is an optionally substituted pyridyl group.

6. A benzamide derivative or a pharmaceutically acceptable salt thereof as claimed in Claim 4, wherein X is a direct bond.

7. A benzamide derivative or a pharmaceutically acceptable salt thereof as claimed in Claim 6, wherein R^1 and R^2 are a hydrogen atom.

8. A benzamide derivative or a pharmaceutically acceptable salt thereof as claimed in Claim 7, wherein R^3 is an amino group.

9. A benzamide derivative or a pharmaceutically acceptable salt thereof as claimed in Claim 5, wherein X is the structure represented by formula (6):

$$-(CH_2)e- \qquad (6)$$

wherein e is ~~as defined above~~ an integer of 1 to 4.

10. A benzamide derivative or a pharmaceutically acceptable salt thereof as claimed in Claim 9, wherein n is 1; and R^1 and R^2 are a hydrogen atom.

11. A benzamide derivative or a pharmaceutically acceptable salt thereof as claimed in Claim 10, wherein R^3 is an amino group.

12. A benzamide derivative or a pharmaceutically acceptable salt thereof as claimed in Claim 5, wherein X is selected from the structures illustrated in formula (7):

$$-(CH_2)g-O-(CH_2)e-,\ -(CH_2)g-S-(CH_2)e-,\ -(CH_2)g-\underset{\displaystyle R4}{\overset{\displaystyle |}{N}}-(CH_2)e- \qquad (7)$$

wherein e, g and R^4 are as defined above.

13. A benzamide derivative or a pharmaceutically acceptable salt thereof as claimed in Claim 12, wherein n is 1; and R^1 and R^2 are a hydrogen atom.

14. A benzamide derivative or a pharmaceutically acceptable salt thereof as claimed in Claim 13, wherein R^3 is an amino group.

15. A benzamide derivative or a pharmaceutically acceptable salt thereof as claimed in Claim 5, wherein X is selected from the structures illustrated in formula (8):



(8)

wherein g, m and R^5 are as defined above.

16. A benzamide derivative or a pharmaceutically acceptable salt thereof as claimed in Claim 15, wherein n is 1; and R^1 and R^2 are a hydrogen atom.

17. A benzamide derivative or a pharmaceutically acceptable salt thereof as claimed in Claim 16, wherein R^3 is an amino group.

18. A benzamide derivative or a pharmaceutically acceptable salt thereof as claimed in Claim 1, wherein n is zero.

19. A benzamide derivative or a pharmaceutically acceptable salt thereof as claimed in Claim 18, wherein Q is selected from the structures illustrated in formula (5).

20. A benzamide derivative or a pharmaceutically acceptable salt thereof as claimed in Claim 19, wherein A is an optionally substituted hetero ring.

21. A benzamide derivative or a pharmaceutically acceptable salt thereof as claimed in Claim 20, wherein A is an optionally substituted pyridyl group.

22. A benzamide derivative or a pharmaceutically acceptable salt thereof as claimed in Claim 21, wherein R^1 and R^2 are a hydrogen atom.

23. A benzamide derivative or a pharmaceutically acceptable salt thereof as claimed in Claim 22, wherein R^3 is an amino group.

24. A benzamide derivative or a pharmaceutically acceptable salt thereof as claimed in Claim 1 represented by formula (9).



(9).

25. A benzamide derivative or a pharmaceutically acceptable salt thereof as claimed in Claim 1 represented by formula (10).



(10).

26. A benzamide derivative or a pharmaceutically acceptable salt thereof as claimed in Claim 1 represented by formula (11).



(11).

27. A benzamide derivative or a pharmaceutically acceptable salt thereof as claimed in Claim 1 represented by formula (12).



(12).

28. An anilide having the structure represented by formula (13):



(13)

[wherein A and B are independently an optionally substituted phenyl or heterocyclic group which has 1 to 4 substituents selected from the group consisting of a halogen atom, a hydroxyl group, an amino group, a nitro group, a cyano group, an alkyl group having 1 to 4 carbons, an alkoxy group having 1 to 4 carbons, an aminoalkyl group having 1 to 4 carbons, an alkylamino group having 1 to 4 carbons, an acyl group having 1 to 4 carbons, an

acylamino group having 1 to 4 carbons, an alkylthio group having 1 to 4 carbons, a perfluoroalkyl group having 1 to 4 carbons, a perfluoroalkyloxy group having 1 to 4 carbons, a carboxyl group, an alkoxycarbonyl group having 1 to 4 carbons, a phenyl group and a heterocyclic group;

Y is a moiety having -CO-, -CS-, -SO- or $-SO_2-$ which is linear, cyclic or their combination and links A and B;

R^3 is a hydroxy or amino group;

the distances between the centroid of ring B (W1), the centroid of ring A (W2) and oxygen or sulfur atom as a hydrogen bond acceptor in the moiety Y (W3) are as follows; W1-W2=6.0 to 11.0 Å, W1-W3=3.0 to 8.0 Å, and W2-W3=3.0 to 8.0 Å.]

or a pharmaceutically acceptable salt thereof.

29. An anilide derivative or a pharmaceutically acceptable salt thereof as claimed in Claim 28, wherein A is an optionally substituted heterocycle; R^3 is an amino group; and Y is a moiety having -CO- which is linear, cyclic or their combination and links A and B.

30. An anilide derivative or a pharmaceutically acceptable salt thereof as claimed in Claim 29, wherein B is an optionally substituted phenyl; W1-W2 is 7.0 to 9.5 Å; W1-W3 is 3.0 to 5.0 Å; and W2-W3 is 5.0 to 8.0 Å.

31. An anticancer drug comprising one or more compounds as claimed in any of Claims 1 to 30 as active

ingredients.

32. A pharmaceutical composition comprising one or more compounds as claimed in any of Claims 1 to 30 as active ingredients.